Nonmetastatic Ewing family tumors: High-dose chemotherapy with stem cell rescue in poor responder patients. results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol

Annals of Oncology

Volumn 22, Issue 5, 2011, Pages 1221-1227

  Ferrari, S ^a   Hall, K Sundby ^b   Luksch, R ^c   Tienghi, A ^d   Wiebe, T ^e   Fagioli, F ^f   Alvegard, T A ^e   del Prever, A Brach ^f   Tamburini, A ^g   Alberghini, M ^a   Gandola, L ^c   Mercuri, M ^a   Capanna, R ^h   Mapelli, S ⁱ   Prete, A ^j   Carli, M ^k   Picci, P ^a   Barbieri, E ^j   Bacci, G ^a   Smeland, S ^b  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^g UNIVERSITY OF FLORENCE   (Italy)

^h Centro Traumatologico Ortopedico   (Italy)

ⁱ ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^j UNIVERSITY OF BOLOGNA   (Italy)

^k UNIVERSITY HOSPITAL OF PADOVA   (Italy)

more..

Author keywords

Chemotherapy induced necrosis; Ewing sarcoma; High dose chemotherapy

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; DRUG MEGADOSE; EVENT FREE SURVIVAL; EWING SARCOMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 79955502856     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq573     Document Type: Article

References (32)

1. Bernstein M, Kovar H, Paulussen M et al. Ewing's sarcoma family of tumors: current management. Oncologist 2006; 11: 503-519.
2. Nesbit ME, Gehan EA, Burgert EO et al. Multimodal therapy for the management of primary nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 1990; 8: 1664-1674.
3. Burgert EO Jr, Nesbit ME, Garnsey LA et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol 1990; 8: 1514-1524.
4. Bacci G, Forni C, Longhi A et al. Long-term outcome for patients with nonmetastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 2004; 40: 73-83.
5. Oberlin O, Habrand JL, Zucker JM et al. No benefit of ifosfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology. J Clin Oncol 1992; 10: 1407-1412.
6. Craft A, Cotterill S, Malcolm A et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol 1998; 16: 3628-3633.
7. Paulussen M, Ahrens S, Dunst J et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 2001; 19: 1818-1829.
8. Grier HE, Krailo MD, Tarbell NJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348: 694-701.
9. Oberlin O, Deley MC, Bui BN et al. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer 2001; 85: 1646-1654.
10. Cotterill SJ, Ahrens S, Paulussen M et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18: 3108-3114.
11. Oberlin O, Patte C, Demeocq F et al. The response to initial chemotherapy as a prognostic factor in localized Ewing's sarcoma. Eur J Cancer Clin Oncol 1985; 21: 463-467.
12. Picci P, Rougraff BT, Bacci G et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol 1993; 11: 1763-1769.
13. Marcus RB Jr, Graham-Pole JR, Springfield DS et al. High-risk Ewing's sarcoma: end-intensification using autologous bone marrow transplantation. Int J Radiat Oncol Biol Phys 1988; 15: 53-59.
14. Horowitz ME, Kinsella TJ, Wexler LH et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 1993; 11: 1911-1918.
15. Atra A, Whelan JS, Calvagna V et al. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transplant 1997; 20: 843-846.
16. Paulussen M, Ahrens S, Burdach S et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998; 9: 275-281.
17. Boulad F, Kernan NA, LaQuaglia MP et al. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma. J Clin Oncol 1998; 16: 1697-1706.
18. Diaz MA, Vicent MG, Madero L. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors. Bone Marrow Transplant 1999; 24: 1157-1159.
19. Fröhlich B, Ahrens S, Burdach S et al. High-dosage chemotherapy in primary metastasized and relapsed Ewing's sarcoma.(EI)CESS. Klin Padiatr 1999; 211: 284-290.
20. Meyers PA, Krailo MD, Ladanyi M et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 2001; 19: 2812-2820.
21. Ladenstein R, Lasset C, Pinkerton R et al. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 1995; 15: 697-705.
22. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980; 153: 106-120.
23. Picci P, Taksdal I, Malaguti MC et al. A good response to induction chemotherapy in Ewing/PNET tumors evaluated by imaging correlates both histological necrosis and survival. An Italian Sarcoma Group/Scandinavian Sarcoma Group Study. Proceedings of ASCO (Abstr 2145). Atlanta, GA 1999 Volume 18.
24. Euro-E.W.I.N.G. Study Committee: EUROE. W.I.N.G. 99 Study Manual: European Ewing Tumour Initiative of National Groups Ewing Tumour Studies 1999. http://euro-ewing.uni-muensterde/ (8 February 2010, date last accessed).
25. McTiernan A, Driver D, Michelagnoli MP et al. High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours. Ann Oncol 2006; 17: 1301-1305.
26. Oberlin O, Rey A, Desfachelles AS et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant. J Clin Oncol 2006; 24: 3997-4002.
27. Ferrari S, Palmerini E, Alberghini M et al. Vincristine, doxorubicin, cyclofosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with non metastatic Ewing sarcoma. Final results of a monoinstitutional study. Tumori 2010; 96: 213-218.
28. Ferrari S, Bertoni F, Palmerini E et al. Predictive factors of histologic response to primary chemotherapy in patients with Ewing sarcoma. J Pediatr Hematol Oncol 2007; 29: 364-368.
29. Elomaa I, Blomqvist CP, Saeter G et al. Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. Eur J Cancer 2000; 36: 875-880.
30. Nilbert M, Saeter G, Elomaa I et al. Ewing's sarcoma treatment in Scandinavia 1984-1990-ten-year results of the Scandinavian Sarcoma Group Protocol SSGIV. Acta Oncol 1998; 37: 375-378.
31. Granowetter L, Womer R, Devidas M et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol 2009; 27: 2536-2541.
32. Paulussen M, Craft AW, Lewis I et al. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 2008; 26: 4385-4393.